Status:
UNKNOWN
The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients
Lead Sponsor:
Hong Kong Baptist University
Collaborating Sponsors:
Hospital Authority, Hong Kong
Conditions:
Covid-19
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
A randomized controlled trial (RCT) will be conducted to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients.
Detailed Description
The proposed study will be a randomized controlled trial (RCT) to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients. The target pop...
Eligibility Criteria
Inclusion
- Participants will be the patients aged 18-65 years old who have been previously diagnosed to be infected with COVID-19 and discharged from local hospitals after treatment with western medicines, and with negative results from COVID-19 virus detection. The subjects will be evaluated for potential pulmonary fibrosis and those who present with the condition resulting from COVID-19 infection will be included.
Exclusion
- Participants will be excluded if they have one or more of the followings: 1) inability to communicate (e.g. cognitive impairment); 2) history of Chinese medicine allergies; 3) incompetent in giving consent.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04799743
Start Date
April 1 2021
End Date
May 1 2022
Last Update
July 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Linda Zhong
Kowloon Tong, Kowloon, Hong Kong